Cargando…

Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29....

Descripción completa

Detalles Bibliográficos
Autores principales: Barat, Maxime, Aldhaheri, Rauda, Dohan, Anthony, Fuks, David, Kedra, Alice, Hoeffel, Christine, Oudjit, Ammar, Coriat, Romain, Barret, Maximilien, Terris, Benoit, Marchese, Ugo, Soyer, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268077/
https://www.ncbi.nlm.nih.gov/pubmed/34206263
http://dx.doi.org/10.3390/cancers13133103
_version_ 1783720277696315392
author Barat, Maxime
Aldhaheri, Rauda
Dohan, Anthony
Fuks, David
Kedra, Alice
Hoeffel, Christine
Oudjit, Ammar
Coriat, Romain
Barret, Maximilien
Terris, Benoit
Marchese, Ugo
Soyer, Philippe
author_facet Barat, Maxime
Aldhaheri, Rauda
Dohan, Anthony
Fuks, David
Kedra, Alice
Hoeffel, Christine
Oudjit, Ammar
Coriat, Romain
Barret, Maximilien
Terris, Benoit
Marchese, Ugo
Soyer, Philippe
author_sort Barat, Maxime
collection PubMed
description SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.51–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. A nomogram based on CT features identified at multivariable analysis yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. ABSTRACT: Purpose: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). Materials and methods: Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. Results: PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Conclusion: CT findings may help discriminate between PPM and PDAC.
format Online
Article
Text
id pubmed-8268077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82680772021-07-10 Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma Barat, Maxime Aldhaheri, Rauda Dohan, Anthony Fuks, David Kedra, Alice Hoeffel, Christine Oudjit, Ammar Coriat, Romain Barret, Maximilien Terris, Benoit Marchese, Ugo Soyer, Philippe Cancers (Basel) Article SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.51–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. A nomogram based on CT features identified at multivariable analysis yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. ABSTRACT: Purpose: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). Materials and methods: Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. Results: PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Conclusion: CT findings may help discriminate between PPM and PDAC. MDPI 2021-06-22 /pmc/articles/PMC8268077/ /pubmed/34206263 http://dx.doi.org/10.3390/cancers13133103 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barat, Maxime
Aldhaheri, Rauda
Dohan, Anthony
Fuks, David
Kedra, Alice
Hoeffel, Christine
Oudjit, Ammar
Coriat, Romain
Barret, Maximilien
Terris, Benoit
Marchese, Ugo
Soyer, Philippe
Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title_full Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title_fullStr Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title_short Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
title_sort utility of ct to differentiate pancreatic parenchymal metastasis from pancreatic ductal adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268077/
https://www.ncbi.nlm.nih.gov/pubmed/34206263
http://dx.doi.org/10.3390/cancers13133103
work_keys_str_mv AT baratmaxime utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT aldhaherirauda utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT dohananthony utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT fuksdavid utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT kedraalice utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT hoeffelchristine utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT oudjitammar utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT coriatromain utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT barretmaximilien utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT terrisbenoit utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT marcheseugo utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma
AT soyerphilippe utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma